About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, May 31st, 2017

The QualityStocks
Daily Stock List


PwrCor, Inc. (PWCO)

We are reporting on PwrCor, Inc. (PWCO) today, here at the QualityStocks Daily Newsletter.

PwrCor, Inc. (previously d/b/a Cornerstone Sustainable Energy) is a cleantech energy technology enterprise. The Company is launching advanced and disruptive solutions for the Waste Heat to Energy, Geothermal, and Solar Thermal markets, and also other applicable markets. PwrCor has its corporate office in New York, New York. The Company lists on the OTCQB.

Furthermore, PwrCor concentrates on energy infrastructure development projects and delivering cleantech energy solutions to commercial and not-for-profit customers. The Company identifies, selects, and implements cost-effective and sustainable energy production technologies for its customers. It assists in different ways to finance those improvements.

Regarding its technology, the PwrCor™ engines utilize proprietary technology, which can cost effectively convert ultra-low-grade heat to usable mechanical or electrical energy. PwrCor™ uses no fossil fuels and does not operate by way of combustion. It has no emissions, and does not process any working fluids that are flammable, harmful to the environment, or expensive to replace.  PwrCor™ is scalable and modular. In addition, it runs relatively silently, all within a small footprint.

Recently, PwrCor announced that it started a program with Consolidated Edison, Inc. to develop a pilot project founded on its proprietary PwrCor™ engine technology. The program is based on PwrCor’s advanced green waste-heat-to-power technology in an application that captures waste steam condensate and converts it to electricity before it is disposed of in the municipal sewer system. Consolidated Edison (Con Ed) one of the largest publicly owned energy companies in the United States.

PwrCor’s proprietary technology captures the steam condensate (hot water) before it is disposed of. The technology can deliver electric power to the building. Also, because of the process, it cools the hot water, eliminating the need to purchase water to temper the over-hot condensate before it can be disposed of in the sewer system.

The structure of the program is to culminate in a Pilot Project installation of a PwrCor engine at a suitable Con Ed customer site. The projection is that site selection will be made during Q3 2017.

PwrCor, Inc. (PWCO), closed Wednesday's trading session at $0.10, even for the day, on 114,859 volume with 13 trades. The average volume for the last 60 days is 46,281 and the stock's 52-week low/high is $0.01/$0.45.

Cardiff International, Inc. (CDIF)

DSR News, PHUB News, Juicy Penny Stocks, Wall Street Mover, CustomerService, SmallCapVoice, FivedollarMovers.net, PennyStockLocks, ResearchOTC, StockRockandRoll, PennyStockLocks, Equity Observer, Value Penny Stocks, StockBomb, StockLockandLoad, PennyStocks24, 007 Stock Chat, PennyStockSpy, Blaque Capital Stocks, Email Stock Picks, JackpotStock Picks, PennyStock MarketBulls, PennyStock PayCheck, RagingStock Bull, Super Hero Stocks, and Xtreme Stock Picks reported on Cardiff International, Inc. (CDIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cardiff International, Inc. is a holding company taking advantage of proven management in private companies that become subsidiaries under the Cardiff umbrella. Cardiff targets acquisitions of mature, high growth, niche companies. The Company’s emphasis is not industry or geographic-specific. Its focus is on proven management, market, as well as margin. Cardiff International is based in Fort Lauderdale, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Cardiff International’s strategy identifies and empowers select income-producing middle market private businesses, technology companies, and commercial real estate properties. Cardiff International provides these companies the enhanced ability to raise money for operations or expansion, and an equity exit and liquidity strategy for the owner, heirs, and/or investors. For investors, Cardiff provides a diversified lower risk to protect and safely enhance their investment through continually adding assets and holdings.

Earlier in May, Cardiff International announced it signed a Letter of Intent (LOI) agreement under which MedicaMetrix will merge into Cardiff International as its subsidiary, MedicaMetrix, Inc., in an all-stock transaction valued at roughly $6 million. MedicaMetrix is the creator of ProstaMetric®. This is a medical device for more effective prostate cancer diagnosis and monitoring with regulatory approval (CE Mark – October 2016).

This market-expanding merger provides Cardiff International entry into the medical device field. Cardiff International’s total assets will now top $20 million. This includes the $9 million in acquired MedicaMetrix assets.

Last week, Cardiff International, NMS Capital Group (NMS), and Prolific Media Holdings announced that all parties signed an LOI agreement. With this agreement, all parties have created Red Room Capital (RRC), which is a private equity fund centered on investments within the entertainment, media, and technology industries.

NMS Capital Group, LLC/NMS Equity Partners, LLC, is a foremost global focused investment firm. It has investments in businesses across manifold asset classes. Prolific Media Holdings is an all-in-one solution for astute brands in Media and Entertainment. Prolific Media has operations ranging from Augmented Reality and Immersive Entertainment to Studio Film Co-financing, Music and Event Production.

RRC will provide investors access to marquee high profile movies, TV shows, media distribution, as well as new technology related industries. RRC has assembled a collection of projects that meet the requirements set by Cardiff International to lessen investor risk.

Cardiff International, Inc. (CDIF), closed Wednesday's trading session at $0.11, down 18.52%, on 5,501 volume with 3 trades. The average volume for the last 60 days is 95,609 and the stock's 52-week low/high is $0.04/$0.50.

AG&E Holdings, Inc. (AGNU)

MarketWatch, The Business Journal, Zacks, Bloomberg and Investors Hub reported on AG&E Holdings, Inc. (AGNU), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AG&E Holdings, Inc. distributes, repairs, and services electronic components to the casino industry in the United States. It is one of the largest suppliers of gaming parts, used machines, and electronic components in the nation. The Company’s distribution chain reaches the Caribbean & Puerto Rico, Canada, and Eastern and Western Europe. Listed on the OTCQB, AG&E Holdings has its corporate headquarters in Hammonton, New Jersey.

The Company is a global distributor and manufacturer of color video monitors and other related distribution products for an array of markets. These include, but are not limited to, gaming machine manufacturers, casinos, coin-operated video game manufacturers, and other display integrators.

In addition, AG&E Holdings owns American Gaming & Electronics, Inc. (AGE). AGE is a top parts distributor to the gaming markets. It sells parts and services to greater than 700 casinos in North America. AGE also sells refurbished gaming machines on an international basis. Also, AGE installs and services some brands of gaming machines in casinos in North America. AGE has offices in Las Vegas, Nevada; Egg Harbor Township, New Jersey; Hialeah, Florida; and McCook, Illinois.

AGE provides repair service for all types of monitors and JCM bill validators, and sells a comprehensive range of products. Products it carries include JCM bill validators, Wells-Gardner monitors and LCDs, Coin Mechanism coin acceptors, and replacement parts for these products, among other products. AGE buys, refurbishes, as well as markets used gaming machines out of the New Jersey facility.

AG&E Holdings announced on December 1, 2016 that it completed the acquisition of Advanced Gaming Associates LLC (AGA). This month, AG&E Holdings provided an update on the Company’s progress since its acquisition in November 2016 of Advanced Gaming Associates LLC. AG&E moved certain of its operations to better serve its customers. This included moving its Las Vegas, Nevada facility and fulfillment center to a larger facility situated closer to major gaming equipment manufacturers.

Additionally, it included moving its Florida office to Palm Beach - a more central location for its customers.  The Company expects to open a new facility in Illinois in June to better serve Midwest casinos.

Furthermore, AG&E expanded its management team and sales force via the addition of Renee Zimmerman as Chief Financial Officer (CFO), and two new sales representatives that bring considerable experience in the high-end gaming products arena. AG&E also reorganized its sales territories to provide more efficient service and responsiveness to customers.

Moreover, AG&E is nearing completion of its license renewals and update process for this year. The Company has also received six additional state, tribal, and global licenses.

AG&E Holdings, Inc. (AGNU), closed Wednesday's trading session at $0.218, even for the day, on 373 volume with 2 trades. The average volume for the last 60 days is 37,426 and the stock's 52-week low/high is $0.11/$0.39.

NABUFIT Global, Inc. (NBFT)

Innovative Marketing reported earlier on NABUFIT Global, Inc. (NBFT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NABUFIT Global, Inc. is the parent company of NABUFIT Global, ApS, which is the developer of the NABUFIT fitness system. The design of the NABUFIT fitness application is to be used by anyone, anywhere, and at any time. NABUFIT is an online fitness platform for health and well-being through physical exercises, nutrition, and lifestyle. The platform provides an interactive, customized experience based on the workouts and participation of Sports Stars. NABUFIT Global has offices in Denmark and in New York City (U.S. Headquarters).

The development is based in Denmark, where the Company is developing an online fitness platform and a mobile application that connects to existing and future monitoring devices – wearables and more. The NABUFIT system is a leading-edge new training portal. It enhances users’ workouts through providing expert advice from professional trainers, health experts, and international sports stars. The NABUFIT app features training sessions designed and conducted by highly qualified experts and stars of several generations of sports.

The NABUFIT fitness application gives users the opportunity to improve their workouts with advice and mentoring from global sports stars. The purpose of this platform is to inspire and motivate users to live healthier and more active lives via customized workout and nutrition plans. The NABUFIT app is to be offered in the German, Chinese, Spanish and Portuguese languages, in addition to the English language.

NABUFIT Global ApS has a partnership with LX Sports Marketing LTDA, as its business development and social media management partner in Brazil. As NABUFIT Global ApS’ social media partner, LX Sports is developing social media and marketing strategies to promote the NABUFIT app in Brazil.

NABUFIT signed the Brazilian football star Neymar Jr. as an international ambassador. NABUFIT Global has debuted its workout routines and videos of Neymar Jr. on its App. More exercise videos will be released throughout 2017.

Last week, NABUFIT Global announced the signing of a marketing agreement with SINA Sports, a division of SINA Corp. (SINA). NABUFIT will be using SINA’s services for the promotion of its NABUFIT App in China. This includes Chinese social media management by way of the SINA platform and Weibo.

The twelve-month agreement permits SINA and NABUFIT to create and publish in cooperation numerous landing pages to boost traffic and obtain registered users to the NABUFIT App. SINA has greater than 300 million visitors to their platform monthly.

NABUFIT Global, Inc. (NBFT), closed Wednesday's trading session at $0.20, even for the day, on 5,500 volume with 1 trade. The average volume for the last 60 days is 5,561 and the stock's 52-week low/high is $0.13/$2.75.

Intrusion, Inc. (INTZ)

Marketbeat, OTC Markets Group, Penny Omega, and OTC Picks reported earlier on Intrusion, Inc. (INTZ), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Intrusion, Inc. is a worldwide provider of entity identification, high speed data mining, cybercrime, and advanced persistent threat detection products. The Company has a long track record of delivering proven, strong, network monitoring and analysis solutions to high profile customers. These include Fortune 500 financial services companies and the U.S. government. Intrusion is based in Richardson, Texas. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Intrusion’s products help protect critical information assets through quickly detecting, protecting, analyzing, and reporting attacks or misuse of classified, private, and regulated information for government and enterprise networks. The Company’s product families include TraceCop™ for identity discovery and disclosure, and Savant™ for network data mining and advanced persistent threat detection.

TraceCop™ is a set of Internet monitoring and tracking products. TraceCop™ provides exceptional capabilities for the identification of malicious and illegal activities based on historical and current Internet usage data. At the heart of the TraceCop offering is a first-rate data collection process that continuously collects, processes, and stores massive amounts of historical Internet usage and traffic data into the TraceCop Databases.

Intrusion’s Savant™ is a transparent network data capture and analysis solution. It brings science into corporate decision making. Savant is a purpose-built appliance. It performs a unique, real-time, transparent data capture and analysis of all content across a company’s network.

Intrusion has its Secure Taps™ - Network Taps Products. It offers a collection of secure network taps, which enable easy, quick, and strong deployment of any of the Company’s network security appliances. Secure Taps permits the connection of a Compliance Commander Sentry appliance to any network in just a few seconds of work where it is completely transparent to the network.

Earlier this month, Intrusion announced financial results for the quarter ended March 31, 2017. The Company’s Net Loss was $351,000 in Q1 2017, versus a Net Loss of $544,000 for Q1 2016.  Revenue for Q1 2017 was $1.56 million, versus $1.51 million for Q1 2016. Gross Profit Margin was 63 percent of revenue in Q1 2017, versus 64 percent in Q1 2016.

G. Ward Paxton, Intrusion’s President and Chief Executive Officer, said, “We booked $2.3 million of orders in the first four months of 2017 consistent with the $2.3 million of orders in the first four months of 2016.  Gross profit as a percent of revenue was 63 percent in the first quarter of 2017, slightly below our goal of 65 percent, due to product mix.  Our top priority in 2017 is to increase sales.  We have significantly increased our sales pipeline from new potential customers.  At this time, our pipeline of TraceCop business includes fourteen new customers and five existing customers.  Our pipeline of Savant business includes nine new customers and two existing customers.” 

Intrusion, Inc. (INTZ), closed Wednesday's trading session at $0.41, down 6.80%, on 3,000 volume with 2 trades. The average volume for the last 60 days is 4,495 and the stock's 52-week low/high is $0.12/$0.9997.


The QualityStocks
Company Corner


InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.31, up 5.26%, on 761,243 volume with 299 trades. The stock’s average daily volume over the past 60 days is 1,030,277, and its 52-week low/high is $0.51/$0.72.

InMed Pharmaceuticals is pleased to announce the closing today of its previously announced public offering (the "Offering"). Pursuant to the Offering, the Company issued 12,788,000 units (the "Units") at a price of $0.45 per Unit, for aggregate gross proceeds to InMed of $5,754,600. The Offering was completed with a syndicate of underwriters led by Canaccord Genuity Corp. and including Eight Capital along with Roth Capital Partners, LLC serving as placement agent for sales of Units in the United States (collectively, the "Underwriters"). The 12,788,000 Units issued include 1,668,000 Units issued and sold pursuant to the over-allotment option granted by the Company to the Underwriters, which was exercised in full.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.4255, up 2.53%, on 455,751 volume with 939 trades. The stock’s average daily volume over the past 60 days is 333,976, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

NetworkNewsWire Announces Editorial Discussing the Potential of Cannabis-Based Therapies for Pain Management

IGC Appoints Medical Advisor Craig Cheifetz, M.D. to Consult on the Development of Cannabis-Based, Combination Therapies

IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain

Players Network, Inc. (PNTV)

The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.07, up 9.20%, on 4,069,908 volume with 214 trades. The stock’s average daily volume over the past 60 days is 1,819,689, and its 52-week low/high is $0.0023/$0.0738.

Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.

Green Leaf Farms Holdings, LLC (Green Leaf)

Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.

Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.

They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.

Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.

Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.


WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.

Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.

WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.

By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.

Marijuana and Media Strategy

While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer

Players Network, Inc. Company Blog

Players Network, Inc. News:

Player's Network Subsidiary Awarded Medical Marijuana Licenses

Player's Network, Inc. Launches Major Shareholder Communications Initiative

Player's Network, Inc. Announces Launch of Marijuana Accelerator Division

Monaker Group, Inc. (MKGI)

The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.35, up 11.90%, on 22,588 volume with 32 trades. The stock’s average daily volume over the past 60 days is 7,180, and its 52-week low/high is $1.71/$4.35.

Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.

NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.

Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.

Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.

In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.

With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.

Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer

Monaker Group, Inc. Company Blog

Monaker Group, Inc. News:

Monaker Launches NextTrip Website and Mobile App Featuring 1.2 Million Instantly Bookable Vacation Rental Properties

Monaker Reports Fiscal 2017 Year-in-Review, Highlighting Travel Industry's First Instant Booking, Customizable Alternative Lodging Booking Engine

Monaker Group to Attend the Oppenheimer Emerging Growth Conference in New York City on May 16th

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $0.95, up 6.74%, on 63,694 volume with 62 trades. The stock’s average daily volume over the past 60 days is 70,776 and its 52-week low/high is $0.12/$2.75.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com, Inc. Announces its New Subsidiary Chinesehempoil.com, Inc. and the Launch of its First Premium Hemp Health Product Line 'OptHemp'

ChineseInvestors.com, Inc. (CIIX) Projected To Reach Revenue of $14.8 Million by FY2020 in Consilium Global Research Report

ChineseInvestors.com, Inc. Appoints Summer Yun as CEO of CBD Biotechnology Co., Ltd., Wholly-owned Foreign Entity


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Trader Power News
(MBOT) +68.03%


(TNRG) +47.23%


(FHBC) +23.08%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251